Stratos Wealth Partners LTD. Lowers Stock Holdings in Solventum Corporation $SOLV

Stratos Wealth Partners LTD. trimmed its stake in shares of Solventum Corporation (NYSE:SOLV) by 18.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,476 shares of the company’s stock after selling 780 shares during the period. Stratos Wealth Partners LTD.’s holdings in Solventum were worth $264,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of SOLV. Independent Franchise Partners LLP lifted its position in shares of Solventum by 263.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after acquiring an additional 4,217,570 shares during the period. Boston Partners raised its position in shares of Solventum by 101.3% during the 1st quarter. Boston Partners now owns 3,361,973 shares of the company’s stock worth $255,554,000 after purchasing an additional 1,691,565 shares during the last quarter. Nuveen LLC acquired a new position in shares of Solventum during the 1st quarter worth approximately $35,375,000. Diamond Hill Capital Management Inc. raised its position in shares of Solventum by 139.6% during the 1st quarter. Diamond Hill Capital Management Inc. now owns 577,173 shares of the company’s stock worth $43,888,000 after purchasing an additional 336,282 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Solventum during the 1st quarter worth approximately $23,572,000.

Solventum Stock Down 1.1%

Shares of Solventum stock opened at $71.49 on Friday. The company has a fifty day moving average price of $72.62 and a 200 day moving average price of $72.19. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $85.92. The stock has a market cap of $12.40 billion, a price-to-earnings ratio of 33.10, a price-to-earnings-growth ratio of 2.91 and a beta of 0.50.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.12 billion. During the same period in the prior year, the company earned $1.56 EPS. The firm’s revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on SOLV shares. Wells Fargo & Company lifted their price objective on Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Monday, September 15th. Wall Street Zen downgraded Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 target price (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. Finally, UBS Group initiated coverage on shares of Solventum in a research note on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.